Compare New York Times Co (NYT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Zoetis Inc — how do they compare? New York Times Co trades at $66.6 (market cap $10.74B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc is far larger — about 2.8× New York Times Co's market cap, and Zoetis Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| NYT | ZTS | |
|---|---|---|
Market Cap | $10.74B | $30.29B |
Sector | Media | Health |
52-Week High | $85.86 | $150.61 |
52-Week Low | $54.66 | $71.91 |
Enterprise Value | $10.14B | $37.86B |
Dividend Yield | 1.38% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight strong operational performance, supported by rising revenue and net income margins. The stock's valuation metrics include a P/E of 28.32 and P/S of 3.75, while positive cash flow trends and a dividend payment reflect financial stability.
Outlook remains cautiously optimistic with a consensus price target of $76.00, offering potential upside. Key risks include ongoing legal challenges with OpenAI over copyright issues and competitive pressures in digital media. Institutional interest is evident, but regulatory and market sentiment uncertainties warrant monitoring for sustained growth.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
